Clinical Trials

Contact Us

Lung Cancer

EA5152 – temporarily closed 8/8/18

A Randomized Phase II Trial of Nivolumab, Cabozantinib Plus Nivolumab, and Cabozantinib Plus Nivolumab Plus Ipilimumab in Patients with Previously Treated Non-Squamous NSCLC


Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination with Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer


Phase II Study of AZD9291 (Osimertinib) in Advanced NSCLC Patients with Exon 20 Insertion Mutations in EGFR

S1400K (NCT# pending) Requires prior entry to S1400 screening study.

A Phase II Study of ABBV-399 (Process II) in Patients with C-Met Positive Stage IV or  Recurrent Squamous Cell Lung Cancer (LUNG MAP SUB-STUDY)

S1400F (NCT03373760) Requires prior entry to S1400 screening study.

A Phase II Study of MED14736 (Durvalumab) Plus Tremelimumab as Therapy for Patients with Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (LUNG-MAP NON-MATCH SUB-STUDY)

A221504 (NCT03087708)

A Randomized, Double-Blind, Placebo-Controlled Pilot of Naloxegol (an Oral, Selective Peripheral Opioid Receptor Antagonist) in Advanced Non-Small Cell Lung Cancer (Adenocarcinoma)

NRG LU002 (NCT03137771)

Maintenance systemic therapy versus consolidative sterotactic body radiation therapy (SBRT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer: A randomized phases II/III trial.

NRG CC003 (NCT02635009) – Temporarily Closed

Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer

Alliance C30610 (NCT00632835)

Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide

SWOG S1400 (NCT02154490)

A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-MAP)